孟鲁司特对哮喘患儿胸腺和活化调节趋化因子的干预作用  

Intervention effect of montelukast on thymus and activation-regulated chemokine in children with asthma

作　　者：柯伟群 谭葵花 杨小金 申宇站 肖勇 黄小池 

机构地区：[1]深圳市平湖镇人民医院儿科,广东省深圳518111

出　　处：《中国基层医药》2011年第8期1052-1054,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨孟鲁司特对哮喘患儿胸腺和活化调节趋化因子（TARC）的干预作用，探寻儿童哮喘新的治疗方案。方法100例哮喘患儿随机分两组，哮喘孟鲁司特治疗组（50例）予口服孟鲁司特，哮喘布地奈德治疗组（50例）予布地奈德雾化吸入，同期在该院儿科住院的急性支气管炎无喘患儿50例为对照组雾化吸入生理盐水，检测各组用药前及用药后血清、痰液TARC的含量。结果用药前哮喘组TARC的含量明显高于对照组（P〈0．05），用药后孟鲁司特治疗组与布地奈德治疗组TARC的含量均明显下降（P〈0．05），下降幅度与对照组比较差异有统计学意义（P〈0．05），孟鲁司特治疗组与布地奈德治疗组TARC的下降幅度无明显差异（P〉0．05）。结论TARC参与了儿童哮喘气道炎症的发生，孟鲁司特可减轻哮喘患儿TARC的水平，缓解患儿哮喘症状，且用药方便、安全性高。Objective To study the intervention effect of montelukast on thymus and activation-regulated chemokine（TARC） in the children with asthma. Methods 100 children with asthma were randomly divided into montelukast （LTRA） group（ n =50） and budesonide（BUD） group（ n = 50） ,the LTRA group was treated with montelukast,the BUD group was treated with budesonide ,50 children without asthma as control group were inhaled NS. Before and after 7 days treatment,the asthma symptoms、FEVl、eoneentration of TARC were measured. Results Before treatment,the concentration of TARE in asthma group was significantly higher than control group （ P 〈 0.05 ）. After treatment,the concentration of TARE in BUD group and LTRA group was significantly decreased（ P 〈0.05） ,but the difference between these two groups was not signifieantl（ P 〉 0.05 ）, the concentration of TARC in control group was not significantly decreased （P 〉 0.05 ） ;the symptoms were better after treatment in BUD group and LTRA group, （P 〈 0,05 ） , and the pulmonary function was significantly improved after treatment in BUD group and LTRA group （ P 〈 0.05）. Conclusion TARC was the important factor in children asthma. Montelukast could block the production of TARE, and was more convenient and safe for children asthma.

关 键 词：哮喘 孟鲁司特 胸腺和活化调节因子哮喘 肺功能 儿童 

分 类 号：R72[医药卫生—儿科]